Abstract: The subject invention relates to recovery of cryopreserved plant cell cultures after cryopreservation. The use of canine IL-4 and human gamma interferon is exemplified in some preferred embodiments.

Abstract: A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, esterase activity, and eosinophil content of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, esterase activity, nitrite content, and eosinophil content.

Abstract: There is disclosed a process for the purification of pharmacologically active proteins based on the use of the cationic exchange chromatography on a solid matrix carried out at a more basic pH, i.e. higher, in respect of the pH corresponding to the isoelectric point, pI, of the proteins to be purified, pH at which however said proteins still remain absorbed. Buffer solutions with values of pH and of ionic strength adjusted from time to time to the kind of pharmacologically active protein to be purified are used in order to obtain such a result. The process is mainly addressed to the purification of the interferon and albumin proteins.

Abstract: Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be used for various analytical or other methods.

Abstract: Disclosed is a method for differentiating human peripheral blood granulocytes which comprises cultivating the granulocytes in the presence of an interferon and acting an immune complex on said granulocytes in the presence of a chemiluminescent substance, and measuring the chemiluminescent amounts induced. It contributes to the screening of patients suffering from serious infectious diseases or a range of inflammations, and is advantageous for monitoring the curative effects for those patients.

Abstract: A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.

Abstract: The subject invention concerns a novel process for the early detection of insulin dependent diabetes (IDD). The novel process described here enables the detection of the onset of IDD before clinical symptoms appear. The novel process involves the detection, in a sample of biological fluid, of an autoantibody which is highly specific to individuals who will later develop the clinical manifestations of IDD. Novel treatments for the prevention of IDD are also described.

Abstract: A composition and method for detecting Crohn's disease include the use of serological testing as a rapid and simple way to diagnose Crohn's disease. The serological tests were based on the use of the two recombinant clones isolated from an M. paratuberculosis genomic library that expressed 35K and 36K MW antigens. Antigen p35 was isolated from Johne's disease sera (acid-fast bacilli form) and p36, from human CD sera (spheroplast form). The combined use of p35 and p36 recombinant antigens provides a highly specific and sensitive test to demonstrate the humoral immune response of CD patients to M. paratuberculosis. A serologic kit is disclosed including the composition including the combined p35 and p36 antigens. A treatment methodology utilizes antimycobacterial drugs, preferably upon patients prescreened for the presence of M para.

Abstract: Bacterial infections are treated by the administration of alpha-interferon at a dosage of from about 0.1 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The method is particularly suitable for the treatment of antibiotic-resistant infections. IFN-.alpha. is administered in solution or in the form of a saliva-dissolvable lozenge.

Abstract: The invention provides a method for inhibition of proliferation of primitive hematopoietic progenitor cells and hematopoietic stem cells, by incubating preparations containing said cells with IFN-.gamma.. The method is especially useful for protecting said cells during purging techniques using cytotoxic treatment, and for protection of said cells during in vivo cytotoxic treatment.

Abstract: Provided are microparticle forms of carbon, carbon catalysts and carbon-containing electrically conductive materials which are covalently linked to peroxidase. The carbon:peroxidase conjugates are suitable for use as substrates in conventional electrodes. Surprisingly, the conjugates display very little sensitivity to known interfering substances and thus are suitable for use as interference free electrodes.

Abstract: The present invention relates to novel, stable recombinant gamma interferons exhibiting in greater or less degree the antiviral and antiproliferative activity in humans and pH 2 labile properties characteristic of native human gamma interferon. The amino acid sequence of such an interferon comprises, from the N terminus: ##STR1## wherein X is a methionine residue or hydrogen and Y is a glutamine residue or, where X is hydrogen, Y is either a glutamine or a pyroglutamate residue.

Abstract: A species-specific DNA-DNA hybridization probe prepared using an isolated whole chromosome of a lower eukaryote as template. The probe is useful for the detection of conspecificity in lower eukaryotes selected from the group consisting of yeast and molds.

Abstract: An in vitro method of detecting a cell-mediated immune response to a specific antigen, comprising incubating a whole blood sample with the specific antigen and detecting the presence of gamma interferon released by sensitized lymphocytes in the whole blood sample as an indication of a cell-mediated immune response to the specific antigen.

Abstract: An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification to homogenity of intact recombinant human immune interferon.

Abstract: New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The chimeric proteins include at least one epitope of leukotoxin fused to an active fragment of a cytokine. The chimeric proteins can be used in a vaccine composition. Also disclosed are methods of vaccination as well as methods of making the proteins employed in the vaccines.

Abstract: Multiple copies of a foreign DNA I coding for the production of a protein may be introduced into eucaryotic cells by cotransforming suitable cells with foreign DNA I and with foreign DNA II which includes a functionally deficient, amplifiable gene coding for a selectable or identifiable trait, preferably carried on the same DNA molecule as a foreign DNA III, which includes a functional, amplifiable gene coding for another selectable or identifiable trait. The cotransformation is carried out under suitable conditions permitting selection or identification of cells expressing the gene on DNA I or that on DNA III, but not that on DNA II. The cotransformed cells so identified or selected are recovered and cloned under conditions where the functionally deficient gene on DNA II is expressed. Cells expressing the gene on DNA II are recovered. They contain multiple copies of DNA I. This method can be used to produce mRNA transcripts or protein products such as human and animal growth hormone, insulin and the like.

Abstract: Compositions having protein kinase C-modulatory, anti-inflammatory and other activities are disclosed. The compounds are derived from aromatic heterocyclic compounds of the indole, indene, benzofuran and benzothiophene class.

Abstract: A new polypeptide, called IFN-.alpha.76, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.

Abstract: An improved process for recovering and purifying lipophilic recombinant proteins such as human .beta.-interferon and interleukin-2 from their hosts yields a protein preparation which may be formulated into a stable pharmaceutical composition having a therapeutically effective amount of the biologically active recombinant lipophilic protein dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier medium at a pH of 6.8 to 7.8 which medium also contains a stabilizer for the protein, such as human serum albumin, normal serum albumin and human plasma protein fraction.

Abstract: There is disclosed a method of treating or preventing viral infections in plants wherein an animal interferon is applied to the plants.

Abstract: A new polypeptide, called IFN-.alpha.54, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.

Abstract: A new polypeptide, called IFN-.alpha.61, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.

Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host IFN, either constitutive or inductive.

Abstract: Disclosed is a complete description of the preparation of novel, recombinant human immune interferon and des-CYS-TYR-CYS recombinant human immune interferon via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The human immune (gamma) interferon (IFN-.gamma.), is isolated and characterized in terms of DNA and amino acid sequences, physical attributes and biological activity.

Abstract: Disclosed is a complete description of the preparation of novel, recombinant human immune interferon and des-CYS-TYR-CYS recombinant human immune interferon via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The human immune (gamma) inteferon (IFN-.gamma.), is isolated and characterized in terms of DNA and amino acid sequences, physical attributes and biological activity.

Abstract: A polypeptide having gamma-interferon activity which lacks the amino acid sequence coded for by exon 4, a polynucleotide sequence which codes for said polypeptide, a replicable expression vehicle containing said polynucleotide sequence and a transformed microorganism containing said replicable expression vehicle are disclosed. The transformed microorganism is useful for preparing the polypeptide having gamma-interferon activity.

Abstract: An improved hollow fiber bioreactor system is disclosed that includes an arrangement for removing the plasticizer that is typically found within the hollow fibers of hollow fiber cartridges so as to prevent this material from contaminating the nutrient fluid. The plasticizer is removed without jeopardizing sterility of the bioreactor.

Abstract: It has been found that arginine serves to increase the receptivity of cells to lymphokines such as interleukin-2 and interferon. An improved method for treating a mammal with one or more lymphokines is disclosed wherein said improvement comprises administering said one or more lymphokines to said mammal in combination with an amount of arginine effective to increase the receptivity of cells of said mammal to said one or more lymphokines.

Abstract: A novel polypeptide which is at least equivalent in biological activity to IFN-.gamma. and is resistant to dimerization and polymerization, a transformant which carries a DNA coding for a novel polypeptide, and a method of producing a novel polypeptide from the culture of the transformant.The DNA coding for the novel polypeptide can be produced, for example, starting with a known plasmid which contains the IFN-.gamma. gene (cDNA), namely pHITtrp1101 or pHITtrp 1201.Insertion of this DNA into a vector followed by introduction into a host gives the transformant. An antibody column is used for the purification of the polypeptide from the culture.The novel polypeptide produced can be used as an antiviral agent or an antitumor agent.

Abstract: Described are modified human gamma interferons, genes coding for their synthesis and plasmids containing and capable of expressing these genes.

Abstract: The invention relates to a process for the isolation and purification of .alpha.-interferons by (a) dissolution of the interferon-containing crude product in guandine. HCl solution and precipitation by dilution with water and/or (b) by chromatography on an HIC column under renaturing conditions.

Abstract: Disclosed is a novel DNA which shows complementarity to human interferon-.gamma. mRNA, a recombinant plasmid containing the DNA, a microorganism containing the recombinant plasmid and a method of producing the same as well as a process for producing a polypeptide having human interferon.gamma. activity using the microorganism.

Abstract: Partial sequences of human-.gamma.-interferon, comprising aminoacid sequences 5 to 127, 1 to 127 and 5 to 146, having biological activity. These partial sequences can be obtained by a genetic engineering process, for which purpose the appropriate DNA sequences are chemically synthesized. The DNA sequences are incorporated in hybrid plasmids, and the latter are introduced into host organisms and their expression is induced there. The biologically active polypeptides are suitable, as is human-.gamma.-interferon, for medicaments.

Abstract: A process for purifying a protein and particularly the purification of a protein, such as gamma interferon, that forms highly insoluble aggregates during the growth of host cells transformed with DNA sequence coding for the protein.

Abstract: A method of purifying a polypeptide having a physiological activity such as one having interferon activities from a culture mixture of a microorganism obtained by a recombinant DNA technique and capable of producing the polypeptide is disclosed. The method comprises subjecting the cultured cells to extraction and purification in the presence of a salt of zinc or copper and polyethyleneimine thereby inhibiting decomposition and denaturation of the polypeptide. The extracted polypeptide can be further purified by column chromatographies using a column containing an anion exchange resin, column containing a cation exchange resin and column containing a gel filtration resin.

Abstract: Methods are provided for the treatment of pathological conditions connected with the production of interferons which destroy the immune system and possess damaging action on the cell system of mammals. Interferons are removed from the blood of mammals in two general methods. According to the first method antibodies to the interferons are introduced parenterally into the bodies of the mammals. In the second method continuous removal of interferon is achieved for example by extracorporeal perfusion of the blood of the patient through the substances which absorb, adsorb, disintegrate, or inactivate the biological activity of the interferons. HTLV-III/LAV virus is also removed by these methods.

Abstract: A biologically active interferon can be administered to an animal in conjunction with the administration of a vaccine to improve the vaccine efficiency and allow the use of a smaller vaccination dose. This procedure will cause a less severe vaccine infection in the animal than if no interferon was administered.

Abstract: A polypeptide having interferon activity which has an amino acid sequence corresponding to an amino acid sequence of an interferon selected from rIFN-.alpha., hybrid rIFN-.alpha., rIFN-.beta. and rIFN-.gamma. interferons in which at least one cysteine residue in the amino acid sequence has been replaced by an amino acid residue which is incapable of forming intermolecular disulfide bonds is provided. There are also provided a dsDNA sequence encoding the novel polypeptide; a replicable plasmidic expression vehicle containing the dsDNA encoding the novel polypeptides of the invention; a microorganism which has been transformed with the replicable plasmidic expression vehicle; and a method of preparing the dsDNA which encodes the novel polypeptides of the invention.

Abstract: The invention concerns the production of the human fibroblast interferon, IFN-.beta.1 by cells of mammalian origin which are capable of constitutively expressing a DNA sequence encoding for IFN-.beta.1, producing the IFN and secreting it into the surrounding culture media.A specific embodiment of the invention comprises a methotrexate resistant chinese hamster ovary cell containing one or more pSVEIF molecules. The pSVEIF molecule contains a DNA sequence encoding for human INF-.beta.1 fused about 60 base pairs downstream from SV40 early start gene. The cell is capable of constitutively expressing the sequence encoding IFN-.beta.1, producing IFN-.beta.1 glycoprotein and secreting it into the surrounding medium.The invention also concerns methods of producing IFN-.beta. by culturing and growing the cells of the invention, and isolating and purifying the IFN-.beta.1 product.

Abstract: There are disclosed compositions and methods for treating tumors and viruses in humans by administering a combination of gamma interferon and delta-4 alpha-2 (Bgl II-1)/(Bgl II) alpha-1 hybrid interferon, preferably by injection.

Abstract: This invention relates to the microbial production, via recombinant DNA technology, of new human leukocyte interferons, Le IF-K and Le IF-L for use in the treatment of viral and neoplastic diseases, and to the means and end products of such production.

Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 56 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.

Abstract: Production of HuIFN-gamma and assay of blood HuIFN-gamma productivity both using donated blood are disclosed. Human whole blood secrets a high titer of HuIFN-gamma when exposed to an IFN-gamma inducer (e.g. mitogen) in the presence of anticoagulant (e.g. heparin, ACD, and CPD). Blood HuIFN-gamma productivity is determined by titrating the secreted HuIFN-gamma with a suitable procedure (e.g. bioassay, radio-immunoassay, or enzyme-linked immunosorbent assay). The blood of cancer patient is lower in HuIFN-gamma productivity than that of healthy donor. The HuIFN-gamma per se is recovered and purified prior to its prophylactic and therapeutic uses.

Abstract: Novel IFN.alpha.S51B10 and IFN.alpha.S17H9 of this invention are prepared from BALL-1 cell induced with Sendai virus according to the well known recombinant DNA technique. Further, this invention relates to a DNA encoding interferon .alpha.S51B10 or .alpha.S17H9, a recombinant plasmid enabling an expression of interferon .alpha.S51B10 or .alpha.S17H9 in a host microorganism and a microorganism transformed by the recombinant plasmid. These two IFN.alpha.s have antiviral and anti-tumor activity as other subtypes of IFN.alpha. and are useful as medicines for human and animal.

Abstract: An improvement to the process for the production of interferon by adding an inducer to lymphoblastoid cells susceptible to being induced to produce interferon is described wherein the cells are treated with an enhancing agent at, or following, induction. In a preferred aspect the cells are also pretreated, before induction, with a stimulator.

Abstract: A composition of matter comprising a polypeptide of the formula:A-R.sub.1 -B-R.sub.2-22.sup.-Cwherein:A is the amino acid sequence 1-16 of human beta interferon;R.sub.1 is cysteine, serine or alanine;B is the amino acid sequence 18-31 of human beta interferon;R.sub.2-22 are naturally occurring amino acids;C is the amino acid sequence 53-166 of human beta interferon.

Abstract: Certain tellurium compounds have been found to have the ability to stimulate the in vivo and in vitro production of cytokines and their receptors. These compounds may be utilized in the treatment of certain tumors, autoimmune diseases, immune diseases and infectious diseases.

Abstract: Disclosed is a complete discription of the preparation of novel, recombinant human immune interferon via recombinant DNA techniques utilizing any of an assortment of expression vectors and host cultures. The recombinant human immune (gamma) interferon (IFN-.gamma.), is isolated and characterized in terms of its DNA and amino acid sequences, physical attributes and biological activity. A des-CYS-TYR-CYS species is also prepared.